A Study of RC48-ADC in Subjects With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: RC48-ADC 1.5 mg/kg (HER2 Positive)|DRUG: RC48-ADC 2.0 mg/kg (HER2 Positive)|DRUG: RC48-ADC 2.5 mg/kg (HER2 Positive)|DRUG: RC48-ADC 2.0 mg/kg (HER2 Low Expression)
Sponsor: RemeGen Co., Ltd.